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ABSTRACT*
Objective: To evaluate diabetes patients’ self-
monitoring of blood glucose using a community 
pharmacy-based quality assurance procedure, to 
investigate whether the procedure improved the 
quality of the patient performance of self monitoring 
of blood glucose, and to examine the opinions of the 
patients taking part in the study.   
Methods: The results of patient blood glucose 
measurements were compared to the results 
obtained with HemoCue Glucose 201+ by pharmacy 
employees in 16 Norwegian community 
pharmacies. Patient performance was monitored 
using an eight item checklist. Patients whose blood 
glucose measurements differed from pharmacy 
measurements by more than 20% were instructed in 
the correct use of their glucometer. The patients 
then re-measured their blood glucose. If the results 
were still outside the set limits, the control 
procedure was repeated with a new lot of 
glucometer strips, and then with a new glucometer. 
The patients returned for a follow-up visit after three 
months.
Results: During the first visit, 5% of the 338 patients 
had measurements that deviated from pharmacy 
blood glucose values by more than 20% and user 
errors were observed for 50% of the patients. At the 
second visit, there was no significant change in the 
analytical quality of patient measurements, but the 
percentage of patients who made user errors had 
decreased to 29% (p < 0.001). Eighty-five percent 
of the patients reported that they used their blood 
glucose results to adjust medication, exercise or 
meals. Fifty-one percent of the patients reported a 
greater trust in their measurements after the second 
visit. Eighty percent of patients wished to have their 
measurements assessed yearly. Of these patients, 
83% preferred to have the assessment done at the 
community pharmacy.  
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Conclusion: A community pharmacy-based quality 
assessment procedure of patients’ self monitoring of 
blood glucose significantly reduced the number of 
user errors. The analytical quality of the patients’ 
measurements was good and did not improve 
further during the study. The high analytical quality 
might be explained by a selection bias of 
participating patients. Patients also reported 
increased confidence in their blood glucose 
measurements after their measurements had been 
assessed at the pharmacy. 
Keywords: Blood Glucose Self-Monitoring. Quality 
Assurance, Health Care. Community Pharmacy 
Services. Norway.  
EVALUACIÓN DE LA CALIDAD DE LA 
AUTO-MONITORIZACIÓN DE GLUCOSA 
SANGUÍNEA DE PACIENTES EN 
FARMACIA COMUNITARIA 
RESUMEN
Objetivo: evaluar la auto-monitorización de la 
glucemia de pacientes diabéticos que utilizan un 
procedimiento de aseguramiento de la calidad en 
farmacia comunitaria, investigar si el 
procedimiento mejoró la calidad de la ejecución de 
la monitorización del paciente, y examinar las 
opiniones de los pacientes que tomaron parte en el 
estudio. 
Métodos: Los resultados de las medidas de 
glucemia de los pacientes se compararon con los 
resultados obtenidos con un HemoCue Glucose 
201+ por los empleados de la farmacia en 16 
farmacias comunitarias noruegas. Se monitorizó la 
actuación del paciente utilizando un check-list de 8 
puntos. Se educó en el uso del glucómetro a los 
pacientes cuyos valores de glicemia diferían en más 
de un 20% de los medidos en la farmacia. Después 
los pacientes volvieron a medir su glucemia. Si los 
resultados estaban aún fuera de los límites se 
repetía el procedimiento con un nuevo paquete de 
tiras de glucómetro, y después con un nuevo 
glucómetro. Los pacientes volvieron para una visita 
de seguimiento tres meses después. 
Resultados: Durante la primera visita, el 5% de los 
338 pacientes tuvieron mediciones malas que se 
desviaron de las de la farmacia en valores 
superiores al 20% y se observaron errores en el 
50% de los pacientes. En la segunda visita, no hubo 
cambios significativos en la calidad analítica de las 
medias de los pacientes, pero el porcentaje de 
usuarios con errores disminuyó al 29% (p<0,001). 
El 85% de los pacientes informó que utilizaban los 
resultados de su glucemia para ajustar la 
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medicación, ejercicio o comidas. El 51% de los 
pacientes informó que tenían una mayor confianza 
en su medición después de la segunda visita. El 
80% de los pacientes deseaba que se le evaluasen 
sus mediciones de glicemia anualmente. De estos 
pacientes, el 83% prefería que la evaluación se 
hiciese en la farmacia comunitaria. 
Conclusión: Un procedimiento de evaluación de la 
calidad de la auto-monitorización de glucemia 
realizado en farmacia comunitaria redujo 
significativamente el número de errores de los 
usuarios. La calidad analítica de las medidas de los 
pacientes fue buena y no mejoró durante el estudio. 
La alta calidad analítica podría explicarse por un 
sesgo de selección de los pacientes participantes. 
Los pacientes también informaron e un aumento de 
confianza en sus medidas de glucemia después de 
que sus mediciones fueses evaluadas en la 
farmacia. 
Palabras clave: Auto-monitorización de la 
glucemia. Aseguramiento de calidad en salud. 
Servicios de farmacia comunitaria. Noruega. 
INTRODUCTION
Self-monitoring of blood glucose (SMBG) is 
considered essential in the management of 
diabetes.1-5 The utility of the measurements 
depends on the analytical quality of the glucometers 
and strips6,7, patient performance of 
measurements2, and how the patients respond to 
the results. Studies of measurement quality report 
that 9-16% of patient SMBG-results deviate from 
laboratory results by more than 20%.8-11
Measurement quality is lower when glucometers are 
used by patients than by professionals.11 User error 
accounts for a considerable proportion of erroneous 
measurements.11-13 A study in German pharmacies 
found that 83% of patients made at least one SMBG 
user error.14 Some user errors, such as not washing 
hands or using expired strips, may lead to 
erroneous results. Other errors may impact the 
patients’ compliance with SMBG, e.g. when patients 
fail to change lancets in their finger prick devices, 
leading to more painful measurements and patient 
reluctance.14 Regular assessments of patient SMBG 
measurements are necessary and broadly 
recommended1,2,4,15, but guidelines do not specify 
how or by whom these assessments should be 
carried out. Because user errors may lead to poor 
results it is important to check not only the 
instrument and strips but also patient performance. 
Glucometers have been shown to perform 
differently with control solution compared to 
blood16,17, thus relying solely on control solution is 
not sufficient to ensure that the glucometer results 
are correct. Research shows that the few patients 
who perform some form of glucometer control 
usually do so by repeated measurements using a 
single glucometer or by comparing the results of two 
of their own glucometers11, but neither of these 
methods is satisfactory. Few studies have tested 
quality assured, accessible control services for 
glucometers and patient performance of 
SMBG.9,10,12 Neither teaching patients SMBG, nor 
evaluating patient performance is dedicated to one 
group of health professionals in Norway, and neither 
service is routinely offered to patients. 
Diabetes patients visit community pharmacies on a 
regular basis, and most obtain their SMBG 
equipment there. Therefore the pharmacy might be 
well-suited for assessing meter accuracy and 
patient performance.18 However, to increase quality 
the assessment must be incorporated into an 
established system of quality assurance in which 
every link in the chain is assessed on a regular 
basis and educational feedback is provided.19
The aims of this study were (a) to assess the quality 
of Norwegian patients’ SMBG measurements, (b) to 
investigate whether the quality and performance 
could be improved by establishing a control 
procedure at the community pharmacy and by 
giving educational feedback, and (c) to investigate 
patient opinions on receiving this service from their 
community pharmacy. 
METHODS
Pharmacy recruitment: The study was performed in 
cooperation with one of the three main pharmacy 
chains in Norway, in order to ease the planning and 
the execution of the study. The pharmacy chain’s 
professional service manager was asked to choose 
pharmacies suited for participation. Eighteen 
pharmacies were selected based on the inclusion 
criteria that the pharmacy must have suitable 
premises and at least one employee must have 
participated in continuing professional education 
courses on diabetes. This employee was 
responsible for conducting the study at the 
pharmacy and performing the SMBG assessments. 
Prior to study start two pharmacies withdrew from 
the study as the employee intended to be 
responsible for the study left, thus 16 pharmacies 
from 15 different Norwegian cities were included.  
Patient recruitment: Men and women over 18 years 
of age with diabetes mellitus type 1 or 2 and who 
self-monitored blood glucose were recruited. There 
was no upper age limit, but patients in need of the 
assistance of a family member or community nurse 
to perform the measurements were excluded. A 
power-estimation showed that each pharmacy 
needed to include 26 patients (see “Statistics” 
below). A recruitment list was compiled of all 
customers who obtained SMBG equipment from the 
pharmacy during the previous six months. 
Invitations to take part in our study were sent to the 
first 55 people on the list fulfilling the inclusion 
criteria. Patients willing to participate were asked to 
return a signed consent form to the pharmacy and 
select a date and time for the SMBG assessment 
from time-slots suggested by the pharmacy. If fewer 
than 26 patients were recruited, invitations were 
sent to the next patients on the recruitment list. The 
patients were given identification numbers at the 
pharmacies, and names were not disclosed to the 
study coordinator. The study was approved by the 
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National Committees for Research Ethics and by 
the Norwegian Social Science Data Services. 
Assessment of glucometers and SMBG 
performance: To assess glucometers and SMBG 
performance we used a modified version of the 
procedure developed by Kristensen et al.10 for use 
in general practitioners’ (GPs’) offices. Patients 
brought their glucometers and strips to the 
pharmacy. When agreeing on a time for the patient 
visit the pharmacy employee gathered information 
on the type of glucometer used by the patient, and 
familiarized themselves with its use before seeing 
the patient. The first visit started with a structured 
interview to determine age, education, type of 
diabetes, medication use, last recalled HbA1c-
value, the patient’s experiences with SMBG, and his 
or her use of the glucose results. The assessment 
procedure was as follows: The patients were asked 
to perform their blood glucose measurements as 
they would perform them at home. The employee 
assessed the performance according to a checklist 
consisting of eight items (Table 1). The checklist 
included items from the manufacturers’ user-
instructions expected to directly affect the result of 
the measurement, as well as performance-items 
regarded as “good practice”. An example is pricking 
the side of the finger tip where there are less nerve-
endings. Failing to do so will not affect the result of 
the measurement, but may have a negative effect 
on compliance.14 For simplicity, failure to comply 
with any check-list item will in this paper be referred 
to as “user errors”. If the employee observed any 
user errors, the patients were made aware of these 
and shown how to perform the task correctly. Within 
5 minutes of the patient measurement, the 
pharmacy employee took a new sample from a 
different finger. The Norwegian Quality 
Improvement of Primary Care Laboratories 
(NOKLUS) has earlier performed studies that 
compared the precision of samples taken from a 
single finger with the precision of samples taken 
from different fingers, and could not find any 
difference when all samples were obtained within 5 
minutes. Therefore sampling from different fingers 
has been the standard procedure in all subsequent 
studies.10,11,20 The pharmacy employee measured 
the patient’s blood glucose using HemoCue 
Glucose 201+ (HemoCue AB, Ängelholm, Sweden), 
an instrument commonly used at general 
practitioners offices. If the difference between the 
pharmacy and patient’s results exceeded 20% at 
glucose concentrations equal or over 4.2 mmol/L 
(75 mg/dL) or 0.83 mmol/L (15 mg/dL) at glucose 
concentrations <4.2 mmol/L21, the analytical quality 
of the measurement was considered unacceptable. 
The reason for the deviation was sought first in the 
patient’s performance when making the 
measurement. The patient and employee then 
repeated their measurements. If the difference was 
still outside the preset limits, a fresh set of 
measurements was taken using a new lot of strips 
with the patient’s glucometer. If still outside the set 
limits, the pharmacy provided a new glucometer of 
the same brand as the patient’s. Patients that did 
not make user errors or have analytically 
unacceptable results did not receive any 
intervention regarding measurement technique.  
The patients returned to the pharmacy 
approximately 3 months after their initial visit and 
the assessment procedure was repeated. At this 
stage the patients were interviewed about their 
experiences with the pharmacy blood glucose 
service.
Quality control of the new pharmacy service: The 
implementation of a quality ensured glucose method 
in the pharmacy is described in detail in a separate 
paper.22 The main findings will be stated here. The 
HemoCue Glucose 201+ was chosen for use at the 
pharmacies as it is a point-of-care instrument of 
high quality used by the majority of GP offices in 
Norway. Before and during the pharmacies’ controls 
of patient SMBG, a quality control system was 
implemented to ensure traceability of the HemoCue 
Glucose 201+ method to a laboratory method 
traceable to the NIST 965 standard reference 
material. This quality control system consisted of 
four steps: 1) estimation of the variation between 
the HemoCue instruments to be used at the 16 
pharmacies, 2) comparison of results from 
HemoCue with the results of a laboratory glucose 
method (Architect ci8200, Abbott Laboratories, 
Abbott Park, IL, USA) that was validated using the 
NIST standard reference material, 3) monitoring the 
quality of HemoCue by use of internal quality 
controls and 4) participation in an external quality 
assessment scheme provided by NOKLUS.  
The between-instrument precision of the 16 
instruments used by the pharmacies was judged 
satisfactory with an imprecision of <2% in 
normal/high level of glucose and approximately 6% 
in low level. There was no significant bias between 
HemoCue and the laboratory method at the 
normal/high level of glucose (approximately 10 
mmol/L) where most of the measurement results 
were found. The results of the external and internal 
quality controls were satisfactory throughout the 
study.22
All the pharmacy employees participated in a 
training program, including both individual work in 
the pharmacies and a common course day. At the 
end of the course day, the pharmacy employees 
carried out the whole patient control-procedure and 
their performance was assessed by the teachers.22
Statistics: The null hypothesis that the number of 
patients with unacceptable measurements would be 
the same on both the first and second visit was 
tested using the McNemar test for paired 
proportions, with alpha set to 0.05 (2-tailed) and 
power to 0.80. Based on earlier studies, the 
expectation was that approximately 15% of the 
patients would not achieve acceptable 
measurements on their first visit.8-10 The authors 
decided that the smallest improvement of interest 
was a reduction in the number of unacceptable 
measurements from 15% to 8%. This calculation 
provided a proposed sample size of 291 patients. 
Assuming a dropout rate of 30% between the first 
and second visit, the participating pharmacies would 
have to recruit 416 patients, 26 patients per 
pharmacy. Estimating a response rate of 
approximately 50%, each pharmacy was instructed 
to send invitations to 55 patients. Descriptive 
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statistics for the continuous variables are expressed 
as median and range (min-max), whereas 
categorical variables are expressed as frequencies 
and/or percentages. The Pearson chi-square or, in 
the case of a 2x2 table, Fisher’s exact test was 
used to test the patients’ measurements for 
significant (p<0.05) demographic and background 
variable effects. All tests were performed using 
SPSS 13 (SPSS Inc., Chicago, IL, USA), except the 
power estimate, which was performed using the 
statistical software Power and Precision version 2 
(Biostat, Englewood, NJ, USA). 
RESULTS
The 16 pharmacies recruited 338 patients (9-32 
patients per pharmacy) from the 1,146 invited 
patients, a response rate of 29%. The response rate 
varied from 8 to 49% between pharmacies. Patient 
characteristics are reported in Table 2. The majority 
of patients had type 2 diabetes (75%), and 49% of 
all patients used insulin. Half of the patients 
reported their last measured HbA1c value to be 7% 
or lower. The most frequent reason for the patients’ 
choice of their current glucometer was a 
recommendation from pharmacy personnel (45%). 
Forty-four percent of the patients were self-
educated in the SMBG, and 27% were taught at the 
pharmacy. The most frequently stated use of results 
from glucose measurements was to adjust meals 
based on the results (68%). Forty percent used the 
results to adjust their medication, and 40% used 
them to adjust their exercise (multiple answers were 
possible). In total, 85% of the patients actively used 
their results to adjust medication, exercise, or 
meals. Table 3 shows which glucometers were used 
by the patients participating in our study.  
Quality of the SMBG at baseline: Sixty-five percent 
of the patients obtained SMBG results within 10% of 
the pharmacies’ results. Thirty percent of the 
patients’ measurements deviated between 10% and 
20%. Five percent of measurements were of 
unacceptable analytical quality, that is to say they 
deviated by more than 20% from the HemoCue 
result, or, if the measurements were below 4.2 
mmol/L (75 mg/dL), the difference exceeded 0.83 
mmol/L (15 mg/dL)21 (Figure 1).  
At the first visit the pharmacy employees observed 
at least one user error in 156 of the patients (51 %) 
(one pharmacy did not use the checklist, thus n= 
308). The maximum number of user errors for one 
patient was three, and in total 200 user errors were 
registered. Table 1 shows the number of user errors 
per checklist item. Whether user errors were made 
by the patient did not predict the analytical quality of 
his or her measurement (p=0.133). Though 156 
patients made user errors, this resulted in an 
unacceptable quality for only 12 patients (8%). Five 
of the 152 patients (3%) who correctly performed 
the measurements had analytically unacceptable 
results.
Twenty five percent of the patients sometimes or 
often doubted the results of their own 
measurements (Table 4). Patients with type 1 
diabetes were more confident in their results than 
those with type 2 diabetes (p=0.039), and patients 
Table 1. Checklist to evaluate patients’ SMBG performance at the first and second visit to the pharmacy. 
Visit 1a
N=308
Visit 2 
N=249
“No”  “No”  
n % n % 
1. Does the patient have clean hands? (Patient did not wash hands or remove the first drop of blood prior to measuring) 102 33
a 47 19a
2.
Is the patient's sampling technique satisfactory? (e.g. did the patient prick the 
side of the finger pad, did they not squeeze out the blood, is the sample 
applied correctly?) 
49 16 a 11 4a
3. Are the patient's strips valid (i.e. not expired)?  15 5 8 3 
4. Is the measuring device clean? 10 3 4 2 
5. Has the patient calibrated the device? 11 4 1 0 
6. Is the device stored properly? 4 1 3 1 
7. Are the strips stored in their original packaging? 6 2 7 3 
8. Does the patient use enough blood? 3 1 5 2 
 Total number of patient errors 200  86  
a Significant difference between the first and second visit (McNemars test, p < 0.001). 
Table 2. Characteristics of participants according to type of diabetes and use of insulin. 
  T1D T2D using 
insulin
T2D not 
using insulin 
Total 
Total number of patients (%) 82 (25) 81 (24) 169 (51) 332 
Mean age in years (95% CI) 52 (48-55) 66 (63-68) 67 (65-68) 63 
Gender, n (%) Male 44 (54) 44 (55) 98 (58) 186 (56) 
Education, n (%) Primary school 15 (19) 25 (31) 52 (31) 92 (28) 
 High school 34 (42) 41 (51) 67 (40) 142 (43) 
 University 32 (40) 14 (18) 47 (28) 93 (28) 
Knowledge of HbA1c  Know HbA1c value (%) 73 (89) 61 (75) 102 (60) 236 (71) 
 Mean self-reported 
HbA1c % (95%CI)  
7.5 (7.3-
7.8)
7.5 (7.2-7.7) 6.6 (6.5-6.8) 7.1 
Mean years performed SMBG (95 % CI) 15 (13-16) 10 (9-12) 5 (4-6) 6 
T1D, Type 1 diabetes; T2D, Type 2 diabetes. Six patients did not report type of diabetes and have been excluded from this 
table. Years and percents have been rounded to the nearest whole number. Where numbers do not add up to 100, this is 
due to missing data and/or rounding.  
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using insulin were more confident than those who 
do not (p=0.016). Pearson chi-square tests showed 
that gender, age, education, type of diabetes, type 
of instrument, measurement frequency, whether 
patients feel unsure of their results, how results are 
employed, patient knowledge of the HbA1c value, 
self-reported HbA1c value, and the use of drugs 
could predict neither measurements of acceptable 
analytical quality nor patient user errors. Patients 
stating that they were self-taught made significantly 
fewer patient user errors (p=0.026).  
Effects of the SMBG assessment: Between the first 
and second visit, 31 patients (9%) dropped out of 
the study, leaving 307 patients who completed both 
visits. Because the number of drop-outs was lower 
than we anticipated, the number of patients 
participating at both visits was sufficient according 
to our power calculation despite a lower recruitment 
than initially planned. However, because the 
percentage of analytically unacceptable 
measurements during the first visit was only 5 %, a 
decrease in analytically unacceptable 
measurements could not be expected. There was 
no significant change in the percentage of 
analytically unacceptable measurements from the 
first (17; 5%) to the second (19; 6%) visit (Figure 1). 
All 17 patients with unacceptable measurements at 
their first visit returned for a second visit. Only two 
of these patients had unacceptable results at the 
second visit. Table 1 presents the number of errors 
per checklist item during the first and second visit. 
During the second visit, the percentage of patients 
who made user errors had decreased from 51 to 
29%. The number of errors per patient varied from 0 
to 2, with the exception of one patient who made 5 
errors. The total number of user errors decreased 
from 65 per 100 patients (200/308) for the first visit 
to 35 per 100 patients (86/249) for the second visit. 
Because four of the pharmacies did not fill out the 
checklist at the second visit, the number of patients 
was reduced to 249. The decrease in errors was still 
significant if only the 222 patients for whom the 
checklist was used at both visits were included (p < 
0.001).
Follow-up of patients with unacceptable results: Of 
the 17 patients with analytically unacceptable 
measurements at the first visit, four measured 
outside the acceptable limits after receiving training 
from the pharmacy employee and measuring again. 
Two of the four patients obtained measurements 
within the limits when using strips with a new lot 
number, whereas the two remaining patients 
measured within the limits after receiving new strips 
and a new device. At the second visit, 11 of the 19 
patients achieved acceptable quality with their 
second measurement. Of the remaining eight 
patients, four achieved acceptable results when 
using a new lot of strips and three when replacing 
both the strips and the device. Despite replacing 
both the strips and the glucometer, one patient still 
did not achieve acceptable results. A patient follow-
up with a biomedical laboratory scientist concluded 
that the most likely explanation for these results was 
the patient’s high hematocrit value, which is known 
to cause deviating blood glucose results.2
Patient satisfaction: Table 3 presents how the 
patients’ trust in their measurements improved from 
the first to the second visit. A total of 80% of the 
patients returning for a second visit wished to have 
the SMBG assessments performed yearly. Of these 
patients, 83% preferred their community pharmacy 
as the site for the service, 5% preferred the hospital 
outpatient clinic, and 2% the GP’s office. The 
Table 3. Glucometers used by the participating patients and number of patients using each 
meter at the first visit to the pharmacy (glucometers are grouped by the type of strip they 
use).
Visit 1 (n=338) 
Accu-Chek Aviva 28 
Accu-Chek Sensor 58 
Accu-Chek Compact/Compact Plus 56 
Ascensia Elite/Elite XL 31 
Ascensia Breeze/Dex/Dex2 20 
Ascensia Contour 35 
FreeStyle/FreeStyle Mini 30 
GlucoTouch 2 
InDuo/One Touch/One Touch Ultra/Ultra Smart 27 
MediSense Precision QID 1 
MediSense Precision Xceed/Xtra 50 
Table 4. Patient confidence in their self-monitoring of blood glucose measurements before and after the pharmacy 
controls, N= 338. 
First visit Second visit 
n % n % 
Never 150 45 193 67 
Rarely 104 31 63 22 
Sometimes 70 21 30 10 
Quite often 11 3 2 1 
Almost every time I measure 2 1 1 1 
Are you ever unsure that your device 
shows the correct result? 
Missing 1  49  
More sure   157 51 
No change   135 44 
Less sure   14 5 
Following the controls at the 
pharmacy, are you more or less sure 
that your device shows the correct 
result? Missing   49  
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remaining 10% of patients had no clear 
preferences. Thirty-two percent of the patients were 
prepared to pay up to 20 Euros for the service, and 
50% were prepared to pay a maximum of 7.5 Euros. 
The remaining 18% of patients were not willing to 
pay for the service. 
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Figure 1. Difference between the patients’ results and the 
pharmacies’ results plotted against the results of the 
pharmacies at the first (n=338) and the second (n=304) 
visit. Lines represent limits recommended in ISO 15197: ± 
20% at glucose concentrations equal or over 4.2 mmol/L 
(75 mg/dL)  and ±0.83 mmol/L (15 mg/dL) at glucose 
concentrations <4.2 mmol/L (75 mg/dL).21
DISCUSSION
This study is unique in using community pharmacies 
as a site for the control of both the analytical quality 
of patients’ measurements and the SMBG 
performance. In addition, the pharmacies benefitted 
from an established system of quality assurance 
through NOKLUS, thus continuously ensuring the 
quality of the pharmacy measurements.22 By 
performing the controls in this manner, followed by 
the correction of patient or instrument errors, this 
service has the potential to improve the quality of 
patient measurements, thereby improving patient 
management of diabetes. However, this also relies 
on patients reacting appropriately to the results of 
their SMBG measurements. Eighty-five percent of 
the patients reported that they used their 
measurement results actively to adjust medication, 
meals or exercise, but we have not investigated the 
appropriateness of these interventions in this study. 
The analytical quality of patient measurements was 
considerably better in this study than reported in 
earlier studies.8-11 Because 15 of the 17 patients 
with unacceptable measurements at the first visit 
were replaced by 17 new patients with 
unacceptable measurements at the second visit, it 
is possible that the improvement seen with the 
original 15 patients was a result of regression to the 
mean rather than our intervention.23  The high 
analytical quality of the patients’ SMBG in our study 
might be explained by a selection bias since the 
response rate was only 29%, whereas other studies 
have considerably higher response rates.10 Patients 
willing to participating in the study were probably 
more motivated than the non-responders. The 
patients in our study had a self-reported mean 
HbA1c of 7.1%, close to the recommended 7%1 and 
approximately 1 percentage point lower than the 
HbA1c of the patients in Skeie’s study11, supporting 
the notion that the patients in our study are 
comparatively well regulated. Another factor may be 
that, following Skeie’s study in 2002,11 the 
Norwegian National Social Insurance Office 
required all manufacturers to have glucometers 
tested by patients. This requirement may have led 
to greater user-friendliness and more robust 
instruments.24
The percentage of patients with user errors (51%) 
was lower than that reported in the German 
pharmacy study (83%)20 but higher than in the 
Norwegian GPs’ offices study (19%).10 The number 
of user errors in our study was halved at the second 
visit compared to the first, a finding similar to that of 
Müller et al.14 It is difficult, however, to compare 
differences in the number of user errors between 
studies because the number of errors detected 
depends on the checklist used to uncover them. 
Müller et al.14 employed a highly detailed checklist 
compared to ours, which again was more detailed 
than the one used by Kristensen et al.10 In our study 
the most common user errors were not washing 
hands before measuring and poor sampling 
technique. It is possible that the fact that patients 
were aware that they were being assessed may 
have altered their performance, thus they avoided 
more “serious” user errors. The user errors we saw 
in our study did not lead to more measurements of 
unacceptable analytical quality; however, it is 
plausible that the correction of some errors will lead 
to better compliance.14 It would have been 
interesting to investigate whether specific errors 
affected the analytical quality, but the low number of 
unacceptable measurements in our study 
population did not allow for this.  
Contrary to what one might assume, we found that 
patients who were self-taught made fewer user 
errors than those who had received SMBG training. 
Possibly, self-taught patients take a more active 
learning approach and study their glucometer 
manual more thoroughly compared to those who 
received training. Also, because the patients were 
not asked what their education entailed, the training 
in question might have been unsatisfactory, 
providing the patients who received it less 
information than the self-taught patients. It is not 
definite that one would see the same positive effect 
of no training in a less motivated patient group. 
Though the number of analytically unacceptable 
measurements was low in this study population, this 
does not change the fact that the quality of patients’ 
SMBG measurements should be monitored.4 Our 
study found that the participating patients preferred 
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to have their measurements assessed at their 
community pharmacy, and Norwegian pharmacy 
employees have also expressed an interest in 
working more actively in this field.25 In Norway the 
National Insurance Scheme pays for 90 % of the 
expenses connected to diabetes patients’ SMBG. In 
2008 they spent more than 40 million Euros on 
glucometer strips alone.26 A service such as that we 
have described here could help ensure that this 
money is well spent; however a challenge for 
pharmacies considering implementation of a SMBG 
assessment service is to recruit patients most in the 
need of the service. Further studies should focus on 
recruiting patients with HbA1c values above 7.5 - 
8%.
CONCLUSIONS
Five percent of patient measurements deviated from 
the comparison method by more than 20%. The 
analytical quality of the Norwegian diabetes 
patients’ SMBG measurements was better than 
reported in earlier studies, possibly due to the 
selected patient sample. Fifty percent of the patients 
made user errors, but this did not lead to more 
unacceptable measurements. The pharmacy 
service significantly reduced the number of user 
errors and gave the patients more confidence in 
their measurements but did not improve the 
analytical quality of the measurements. 
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